Surgical treatment for oligoprogression in metastasized renal cell carcinoma after medical treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025088

Enrollment

Registered

2022-01-25

Start date

2022-01-25

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C64 C78.0

Interventions

Group 1: The study will enrol patients who have undergone surgery for thoracic metastases in oligoprogressive renal cell carcinoma after medical treatment. All data for the study will be obtained retr

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Patients with oligoprogressive metastatic renal cell carcinoma after drug therapy - Surgical resection of one or more thoracic metastases at the Clinic for Thoracic Surgery, Freiburg, Germany

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Overall Survival	—

Secondary

Measure	Time frame
progression free survival, disease free survival, surgery related mortality and morbidity, duration of hospital stay	—

Countries

Germany

Contacts

Public ContactUyen-Thao Le

Universitätsklinikum Freiburg Klinik für Thoraxchirurgie

antonia.uyen-thao.le@uniklinik-freiburg.de+49 761 27024710

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026